The European Randomized Screening for Prostate Cancer (ERSPC) trial showed a 20% reduction in the PCa-specific mortality among men undergoing screening with serum prostate-specific antigen (PSA) testing and systematic prostate biopsies, compared to those in the control group, after seven years of follow-up [2]. Here, KLK3 is linked to Familial prostate cancer.